Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience
Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, partic...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Wiley-Blackwell Publishing Ltd.
2019
|
| Online Access: | http://hdl.handle.net/20.500.11937/74146 |
| _version_ | 1848763192890621952 |
|---|---|
| author | Goutzamanis, S. Doyle, J. Higgs, Peter Hellard, M. |
| author_facet | Goutzamanis, S. Doyle, J. Higgs, Peter Hellard, M. |
| author_sort | Goutzamanis, S. |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, particularly for “hard-to-reach” populations. Treatment advances and cure will also likely alter the individual experience of living with hepatitis C. However, it is not yet known in what capacity. This paper provides an overview of the population-level impact of DAA treatment, highlighting the need to further our understanding of the impact of treatment on behaviour, health and wellbeing through lived experience and more sensitive patient-reported outcome measures. |
| first_indexed | 2025-11-14T10:59:34Z |
| format | Journal Article |
| id | curtin-20.500.11937-74146 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:59:34Z |
| publishDate | 2019 |
| publisher | Wiley-Blackwell Publishing Ltd. |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-741462019-08-01T07:29:04Z Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience Goutzamanis, S. Doyle, J. Higgs, Peter Hellard, M. Hepatitis C virus contributes to substantial and growing mortality and morbidity. Fortunately, the advent of highly effective interferon-free direct-acting antiviral (DAA) medications and new diagnostic tests has the potential to dramatically alter the epidemiologic trajectory of hepatitis C, particularly for “hard-to-reach” populations. Treatment advances and cure will also likely alter the individual experience of living with hepatitis C. However, it is not yet known in what capacity. This paper provides an overview of the population-level impact of DAA treatment, highlighting the need to further our understanding of the impact of treatment on behaviour, health and wellbeing through lived experience and more sensitive patient-reported outcome measures. 2019 Journal Article http://hdl.handle.net/20.500.11937/74146 10.1111/jvh.13020 Wiley-Blackwell Publishing Ltd. restricted |
| spellingShingle | Goutzamanis, S. Doyle, J. Higgs, Peter Hellard, M. Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience |
| title | Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience |
| title_full | Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience |
| title_fullStr | Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience |
| title_full_unstemmed | Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience |
| title_short | Improving hepatitis C direct-acting antiviral access and uptake: A role for patient-reported outcomes and lived experience |
| title_sort | improving hepatitis c direct-acting antiviral access and uptake: a role for patient-reported outcomes and lived experience |
| url | http://hdl.handle.net/20.500.11937/74146 |